Movement Alert｜Pharmaron Rises 5.33% in Regular Trading, H1 Earnings Forecast Beats Expectations Amid CRO Order Recovery

Market Focus07-22

On July 22, Pharmaron rose 5.33% in regular trading, trading at 24.92 HKD/share, with turnover of approximately 75.31 million HKD.

On the news front, the company previously disclosed its H1 earnings forecast, projecting revenue of 7.47-7.67 billion yuan, up 16%-19% YoY, and attributable net profit of 729.5-771.5 million yuan, up 4%-10% YoY. Notably, newly signed orders surged over 30% YoY, with small-molecule CDMO new orders growing over 50% YoY. Q2 performance showed clear acceleration versus Q1, with Q2 adjusted non-IFRS net profit estimated to grow 22.3% YoY.

At the industry level, the CRO sector is experiencing a broad order recovery, with leading companies reporting backlog growth exceeding 40% YoY. Institutions believe the CXO rebound is supported by fundamentals. Additionally, JP Morgan increased its stake in Pharmaron by approximately 1.29 million shares on July 10, while Daiwa recently initiated coverage with a Buy rating and a target price of 25.5 HKD, citing robust CMC business growth prospects.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1171856876?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-22 09:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1171856876","market":"us","top_or_hot":-1,"title":"Movement Alert｜Pharmaron Rises 5.33% in Regular Trading, H1 Earnings Forecast Beats Expectations Amid CRO Order Recovery","media":"Market Focus","content":"<p><p>On July 22, Pharmaron rose 5.33% in regular trading, trading at 24.92 HKD/share, with turnover of approximately 75.31 million HKD.</p><p>On the news front, the company previously disclosed its H1 earnings forecast, projecting revenue of 7.47-7.67 billion yuan, up 16%-19% YoY, and attributable net profit of 729.5-771.5 million yuan, up 4%-10% YoY. Notably, newly signed orders surged over 30% YoY, with small-molecule CDMO new orders growing over 50% YoY. Q2 performance showed clear acceleration versus Q1, with Q2 adjusted non-IFRS net profit estimated to grow 22.3% YoY.</p><p>At the industry level, the CRO sector is experiencing a broad order recovery, with leading companies reporting backlog growth exceeding 40% YoY. Institutions believe the CXO rebound is supported by fundamentals. Additionally, JP Morgan increased its stake in Pharmaron by approximately 1.29 million shares on July 10, while Daiwa recently initiated coverage with a Buy rating and a target price of 25.5 HKD, citing robust CMC business growth prospects.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Pharmaron Rises 5.33% in Regular Trading, H1 Earnings Forecast Beats Expectations Amid CRO Order Recovery</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Pharmaron Rises 5.33% in Regular Trading, H1 Earnings Forecast Beats Expectations Amid CRO Order Recovery\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-22 09:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 22, Pharmaron rose 5.33% in regular trading, trading at 24.92 HKD/share, with turnover of approximately 75.31 million HKD.</p><p>On the news front, the company previously disclosed its H1 earnings forecast, projecting revenue of 7.47-7.67 billion yuan, up 16%-19% YoY, and attributable net profit of 729.5-771.5 million yuan, up 4%-10% YoY. Notably, newly signed orders surged over 30% YoY, with small-molecule CDMO new orders growing over 50% YoY. Q2 performance showed clear acceleration versus Q1, with Q2 adjusted non-IFRS net profit estimated to grow 22.3% YoY.</p><p>At the industry level, the CRO sector is experiencing a broad order recovery, with leading companies reporting backlog growth exceeding 40% YoY. Institutions believe the CXO rebound is supported by fundamentals. Additionally, JP Morgan increased its stake in Pharmaron by approximately 1.29 million shares on July 10, while Daiwa recently initiated coverage with a Buy rating and a target price of 25.5 HKD, citing robust CMC business growth prospects.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03759","symbol_name":"康龙化成","start_time":0,"source_url":"","article_id":"1171856876","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1171856876","pubTimestamp":1784684970,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 22, Pharmaron rose 5.33% in regular trading, trading at 24.92 HKD/share, with turnover of approximately 75.31 million HKD.On the news front, the company previously disclosed its H1 earnings...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03759":"康龙化成"},"translate_title":"走势提醒|康龙化成常规交易上涨5.33%，CRO订单复苏，上半年盈利预测超出预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03759":1},"content_text":"On July 22, Pharmaron rose 5.33% in regular trading, trading at 24.92 HKD/share, with turnover of approximately 75.31 million HKD.On the news front, the company previously disclosed its H1 earnings forecast, projecting revenue of 7.47-7.67 billion yuan, up 16%-19% YoY, and attributable net profit of 729.5-771.5 million yuan, up 4%-10% YoY. Notably, newly signed orders surged over 30% YoY, with small-molecule CDMO new orders growing over 50% YoY. Q2 performance showed clear acceleration versus Q1, with Q2 adjusted non-IFRS net profit estimated to grow 22.3% YoY.At the industry level, the CRO sector is experiencing a broad order recovery, with leading companies reporting backlog growth exceeding 40% YoY. Institutions believe the CXO rebound is supported by fundamentals. Additionally, JP Morgan increased its stake in Pharmaron by approximately 1.29 million shares on July 10, while Daiwa recently initiated coverage with a Buy rating and a target price of 25.5 HKD, citing robust CMC business growth prospects.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1171856876","isCrawlerRequest":true}